Page 1

25 October 2021 botanix PHARMACEUTICALS Botanix Pharmaceuticals Quarterly Activity Report Key highlights • • and 4C Quarterly Cash Flow Report Botanix's canine atopic dermatitis proof of concept study , BTX1204A , underway following positive data delivered during the initial pilot study in May 2021 BTX 1702 Phase 1b / 2a Rosacea Study is progressing well , and recruitment remains on track despite COVID restraints Highly experienced pharmaceutical executive Dr Jack Hoblitzell appointed as Senior Vice President of Pharmaceutical Development Preparation for the Phase 2 hemodialysis nasal decolonisation study , BTX 1801 , is advancing with formulation and delivery studies underway Strong cash position of $ 19.57 million at quarter end with R & D tax return expected in the coming quarter Philadelphia PA and Perth Australia , 25 October 2021 : Clinical dermatology company , Botanix Pharmaceuticals Limited ( ASX : BOT , “ Botanix ” or “ the Company " ) , is pleased to release its Quarterly Activity Report and Appendix 4C Quarterly Cash Flow report for the period ended 30 September 2021 . Clinical Studies and Drug Development Dermatology : BTX1204A canine atopic dermatitis trial commences Following the receipt of ethics approval , Botanix has now commenced its BTX 1204A proof of concept study in canines with atopic dermatitis across Australia and New Zealand . BTX 1204A is based on a new higher dose formulation of synthetic cannabidiol ( CBD ) in a novel Permetrex ™ formulation which recently demonstrated strong efficacy in killing bacteria and providing separation between drug active and vehicle arms in the successful BTX 1801 Phase 2a study . Up to 45 canines across three dermatology sites will be enrolled and two formulations of BTX 1204A ( high dose and low dose ) and a vehicle arm will be evaluated . Each canine will be treated twice daily with BTX 1204A applied topically , over a 28 - day period . The study will evaluate the treatment's efficacy using the industry standard Enhanced Pruritus Score ( EPS ) and Canine Atopic Dermatitis Extent and Severity Index ( CADESI - 04 ) . This study follows encouraging data from a canine pilot study that completed in May 2021. Further positive outcomes of this new study will support progress towards a late - stage Phase 2b clinical study in humans with atopic dermatitis , as well as provide a number of potential commercial opportunities for the Company to partner with and drive licensing programs across the animal health sector . The potential benefit of BTX 1204A in canine and human atopic dermatitis is supported by studies that indicate synthetic CBD addresses multiple factors of disease pathology , inhibits itch ' and repairs skin